FDA is developing a series of four methodological patient-focused drug development (PFDD) guidance documents to address, in a stepwise manner, how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers for medical product development and regulatory decision making. This series of guidance documents is intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can better inform medical product development and regulatory decision making.
These guidances are part of FDA’s PFDD efforts in accordance with the 21st Century Cures Act and The Food and Drug Administration Reauthorization Act of 2017 Title I.
This webpage contains information and documents related to FDA’s development of the methodological PFDD guidances, including public workshops, draft guidances, and hypothetical scenarios, which are all intended to serve as a basis for dialogue. For an outline of FDA’s planned timeframe for development of the guidance, please refer to the Plan for Issuance of Patient-Focused Drug Development Guidance.
Guidance 1 discusses sampling methods that could be used when planning to collect patient input. It also provides a general overview of the relationship between potential research question(s) and method(s) when deciding from whom to get input (including defining the target population and development of the sampling strategy).
- Final Guidance: Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders.
- Patient-Focused Drug Development Glossary: Standardized nomenclature and terminologies related to patient-focused medical product development
- Hypothetical Case Examples: Provide practical supplemental information to illustrate important concepts present in FDA’s draft guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.
Guidance 2 discusses methods for eliciting information from individuals identified in Guidance 1, gathering information about what aspects of symptoms, impacts of their disease, and other issues are important to patients. It discusses best practices in how to do qualitative research including conducting interviews, development of interview guides, selection of types of survey questions, and considerations for collecting demographics and survey information. It also discusses survey methods and qualitative research topics to help avoid misleading results such as inadvertently priming patients in ways that can lead to results that poorly represent what is important to patients.
Guidance 3 discusses approaches to selecting, modifying, developing, and validating clinical outcome assessments to measure outcomes of importance to patients in clinical trials.
Guidance 4 will address methodologies, standards, and technologies that may be used for the collection, capture, storage, and analysis of clinical outcome assessment (COA) data. The guidance will also address methods to better incorporate COAs into endpoints that are considered significantly robust for regulatory decision-making. This includes methods to define meaningful change in a COA-based endpoint and interpretation of results. The guidance will include information on the format and content required for regulatory submissions incorporating patient experience, in particular COA data.
To get updates about CDER's Patient-Focused Drug Development programs, subscribe to our free email subscription service using the button at the top of the page.